8BBN

SARS-CoV-2 Delta-RBD complexed with BA.2-10 and EY6A Fabs

Summary for 8BBN

• Entry DOI: 10.2210/pdb8bbn/pdb
• Descriptor: EY6A Heavy chain, EY6A light chain, Spike protein S1, ... (5 entities in total)
• Functional Keywords: sars-cov-2, ba.2 mab, rbd, ba.2-36, ba.2-10, viral protein
• Biological source: Homo sapiens; More
• Total number of polymer chains: 15
• Total formula weight: 356011.34

Authors

Zhou, D.,Ren, J.,Stuart, D.I. (deposition date: 2022-10-14, release date: 2023-03-22, Last modification date: 2024-11-13)

Primary citation

Dijokaite-Guraliuc, A.,Das, R.,Zhou, D.,Ginn, H.M.,Liu, C.,Duyvesteyn, H.M.E.,Huo, J.,Nutalai, R.,Supasa, P.,Selvaraj, M.,de Silva, T.I.,Plowright, M.,Newman, T.A.H.,Hornsby, H.,Mentzer, A.J.,Skelly, D.,Ritter, T.G.,Temperton, N.,Klenerman, P.,Barnes, E.,Dunachie, S.J.,Roemer, C.,Peacock, T.P.,Paterson, N.G.,Williams, M.A.,Hall, D.R.,Fry, E.E.,Mongkolsapaya, J.,Ren, J.,Stuart, D.I.,Screaton, G.R.
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Cell Rep, 42:112271-112271, 2023

PubMed Abstract: In November 2021, Omicron BA.1, containing a raft of new spike mutations, emerged and quickly spread globally. Intense selection pressure to escape the antibody response produced by vaccines or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection then led to a rapid succession of Omicron sub-lineages with waves of BA.2 and then BA.4/5 infection. Recently, many variants have emerged such as BQ.1 and XBB, which carry up to 8 additional receptor-binding domain (RBD) amino acid substitutions compared with BA.2. We describe a panel of 25 potent monoclonal antibodies (mAbs) generated from vaccinees suffering BA.2 breakthrough infections. Epitope mapping shows potent mAb binding shifting to 3 clusters, 2 corresponding to early-pandemic binding hotspots. The RBD mutations in recent variants map close to these binding sites and knock out or severely knock down neutralization activity of all but 1 potent mAb. This recent mAb escape corresponds with large falls in neutralization titer of vaccine or BA.1, BA.2, or BA.4/5 immune serum.

PubMed: 36995936
DOI: 10.1016/j.celrep.2023.112271

Experimental method

X-RAY DIFFRACTION (3.58 Å)